Biblio
Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. Crit Rev Oncol Hematol. 2019;141:54-72.
. Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. Haematologica. 2015.
. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts. Expert Rev Hematol. 2021.
.